Focuses on a study on the cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Recommendation of the National Osteoporosis Foundation and the American College of Obstetrics and Gynecology on drug therapy for osteopenic menopausal women; Range of cost per quality-adjusted life-year for women with no additional fracture risk factors.